Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C82492
http://purl.obolibrary.org/obo/NCIT_C82492
|
|---|---|
| Preferred Name | Trastuzumab Emtansine |
| Definitions |
An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. |
|---|---|
| prefLabel | Trastuzumab Emtansine
|
| label | Trastuzumab Emtansine
|
| PDQ_Closed_Trial_Search_ID | 564399
|
| code | C82492
|
| Has_Target | |
| prefixIRI | NCIT:C82492
|
| in_subset |
See more
See less
|
| Display_Name | Trastuzumab Emtansine
|
| Preferred_Name | Trastuzumab Emtansine
|
| FDA_UNII_Code | SE2KH7T06F
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C47H63ClN5O13S
|
| Maps_To | Trastuzumab Emtansine
|
| CAS_Registry | 1018448-65-1
|
| NCI_Drug_Dictionary_ID | 564399
|
| Legacy Concept Name | Trastuzumab-MCC-DM1_Conjugate
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 564399
|
| Accepted_Therapeutic_Use_For | HER2-positive, metastatic breast cancer
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2935436
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |